- Home
- SHPH vs NDRA Comparison
SHPH vs NDRA Comparison
Compare SHPH & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHPH
- NDRA
- Stock Information
- Founded
- SHPH 2012
- NDRA 2007
- Country
- SHPH United States
- NDRA United States
- Employees
- SHPH N/A
- NDRA N/A
- Industry
- SHPH Biotechnology: Pharmaceutical Preparations
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SHPH Health Care
- NDRA Health Care
- Exchange
- SHPH Nasdaq
- NDRA Nasdaq
- Market Cap
- SHPH 2.3M
- NDRA 2.1M
- IPO Year
- SHPH 2022
- NDRA 2017
- Fundamental
- Price
- SHPH $0.31
- NDRA $3.98
- Analyst Decision
- SHPH
- NDRA Strong Buy
- Analyst Count
- SHPH 0
- NDRA 1
- Target Price
- SHPH N/A
- NDRA $50.00
- AVG Volume (30 Days)
- SHPH 1.8M
- NDRA 355.0K
- Earning Date
- SHPH 05-12-2025
- NDRA 05-13-2025
- Dividend Yield
- SHPH N/A
- NDRA N/A
- EPS Growth
- SHPH N/A
- NDRA N/A
- EPS
- SHPH N/A
- NDRA N/A
- Revenue
- SHPH N/A
- NDRA N/A
- Revenue This Year
- SHPH N/A
- NDRA N/A
- Revenue Next Year
- SHPH N/A
- NDRA N/A
- P/E Ratio
- SHPH N/A
- NDRA N/A
- Revenue Growth
- SHPH N/A
- NDRA N/A
- 52 Week Low
- SHPH $0.23
- NDRA $2.97
- 52 Week High
- SHPH $4.71
- NDRA $665.00
- Technical
- Relative Strength Index (RSI)
- SHPH 39.42
- NDRA 51.65
- Support Level
- SHPH $0.23
- NDRA $3.28
- Resistance Level
- SHPH $0.32
- NDRA $3.98
- Average True Range (ATR)
- SHPH 0.07
- NDRA 0.92
- MACD
- SHPH 0.00
- NDRA 0.02
- Stochastic Oscillator
- SHPH 23.65
- NDRA 31.76
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.